TY - JOUR
T1 - Omega-3 Fatty acids-3 fatty acid ethyl esters diminish postprandial lipemia in familial hypercholesterolemia
AU - Chan, Dick
AU - Pang, Jing
AU - Barrett, Hugh
AU - Sullivan, D.R.
AU - Burnett, John
AU - Van Bockxmeer, Frank
AU - Watts, Gerald
PY - 2016/10
Y1 - 2016/10
N2 - © 2016 by the Endocrine Society.
CONTEXT:
Impaired postprandial chylomicron metabolism induces hypertriglyceridemia and may increase the risk of atherosclerotic cardiovascular disease. Omega-3 fatty acid ethyl ester (ω-3 FAEE) supplementation decreases plasma triglycerides. However, its effect on postprandial chylomicron metabolism in familial hypercholesterolemia (FH) has not yet been investigated.
OBJECTIVE:
We aimed to examine the effect of ω-3 FAEE supplementation on postprandial responses in plasma triglycerides, very-low-density lipoprotein (VLDL) apolipoprotein B (apoB)-100, and apoB-48 in FH patients receiving standard cholesterol-lowering treatment.
DESIGN, SETTING, AND PATIENTS:
We carried out an 8-week open-label, randomized, crossover intervention trial to test the effect of oral supplementation with 4 g/d ω-3 FAEE (46% eicosapentaenoic acid and 38% docosahexaenoic acid) on postprandial triglyceride, VLDL-apoB-100, and apoB-48 responses in FH patients after ingestion of an oral fat load.
OUTCOMES MEASURES:
Plasma total and incremental triglyceride, VLDL-apoB-100, and apoB-48 0- to 10-hour area under the curve (AUC).
RESULTS:
ω-3 FAEE supplementation significantly (P <.05 in all) reduced concentrations of fasting plasma triglyceride (-20%), apoB (-8%), VLDL-apoB-100 (-26%), and apoB-48 (-36%); as well as systolic blood pressure (-6%) and diastolic blood pressure (-6%). Postprandial triglyceride and VLDL-apoB-100 total AUCs (-19% and -26%, respectively; P <.01) and incremental AUCs (-18% and -35%, respectively; P <.05), as well as postprandial apoB-48 total AUC (-30%; P <.02) were significantly reduced by ω-3 FAEE supplementation.
CONCLUSION:
Supplementation with ω-3 FAEEs improves postprandial lipemia in FH patients receiving standard care; this may have implications for further reducing atherosclerotic cardiovascular disease in this high-risk patient group.
AB - © 2016 by the Endocrine Society.
CONTEXT:
Impaired postprandial chylomicron metabolism induces hypertriglyceridemia and may increase the risk of atherosclerotic cardiovascular disease. Omega-3 fatty acid ethyl ester (ω-3 FAEE) supplementation decreases plasma triglycerides. However, its effect on postprandial chylomicron metabolism in familial hypercholesterolemia (FH) has not yet been investigated.
OBJECTIVE:
We aimed to examine the effect of ω-3 FAEE supplementation on postprandial responses in plasma triglycerides, very-low-density lipoprotein (VLDL) apolipoprotein B (apoB)-100, and apoB-48 in FH patients receiving standard cholesterol-lowering treatment.
DESIGN, SETTING, AND PATIENTS:
We carried out an 8-week open-label, randomized, crossover intervention trial to test the effect of oral supplementation with 4 g/d ω-3 FAEE (46% eicosapentaenoic acid and 38% docosahexaenoic acid) on postprandial triglyceride, VLDL-apoB-100, and apoB-48 responses in FH patients after ingestion of an oral fat load.
OUTCOMES MEASURES:
Plasma total and incremental triglyceride, VLDL-apoB-100, and apoB-48 0- to 10-hour area under the curve (AUC).
RESULTS:
ω-3 FAEE supplementation significantly (P <.05 in all) reduced concentrations of fasting plasma triglyceride (-20%), apoB (-8%), VLDL-apoB-100 (-26%), and apoB-48 (-36%); as well as systolic blood pressure (-6%) and diastolic blood pressure (-6%). Postprandial triglyceride and VLDL-apoB-100 total AUCs (-19% and -26%, respectively; P <.01) and incremental AUCs (-18% and -35%, respectively; P <.05), as well as postprandial apoB-48 total AUC (-30%; P <.02) were significantly reduced by ω-3 FAEE supplementation.
CONCLUSION:
Supplementation with ω-3 FAEEs improves postprandial lipemia in FH patients receiving standard care; this may have implications for further reducing atherosclerotic cardiovascular disease in this high-risk patient group.
U2 - 10.1210/jc.2016-2217
DO - 10.1210/jc.2016-2217
M3 - Article
C2 - 27490922
SN - 0021-972X
VL - 101
SP - 3732
EP - 3739
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 10
ER -